Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure
Featuring
Professor Subodh Verma | Canada
Related content
Document ID: PC-ASK-100493
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
How has recent evidence and the ESC 2023 guidelines changed management of heart failure?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Full)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)